MARGINAL ZONE LYMPHOMA

This study tests whether adding the drug tafasitamab to a standard two-drug combination (lenalidomide plus rituximab) helps people with relapsed or refractory follicular lymphoma or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who have a…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …

This study tests a drug called obinutuzumab in 56 people with newly diagnosed marginal zone lymphoma who cannot have or have failed local therapy. The goal is to see if this antibody can shrink tumors and control the disease without the harsh side effects of chemotherapy. Partici…

This study tests whether combining two immunotherapy drugs, glofitamab and obinutuzumab, can safely and effectively treat people newly diagnosed with follicular lymphoma or marginal zone lymphoma. The 47 participants have not had any prior lymphoma treatment. The goal is to see i…

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 people with marginal zone lymphoma that has not responded to or has returned after previous treatment. The goal is to see how well the combo works and how safe it is. Participants receive treatment …

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This phase II trial is testing a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (MZL), a type of blood cancer. The study aims to see how well the treatment controls the disease and how safe it is. About 175 participants with dif…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then te…

This study tests a new drug combination (Copanlisib and Rituximab) for people with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if this chemotherapy-free approach can shrink tumors as well as standard chemo but with fewer side effects. The trial include…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tracks about 50 people who previously received an experimental CAR T cell therapy for several types of lymphoma. The goal is to watch for long-term side effects and check how well patients do over 15 years. No new treatment is given, but patients can receive other canc…

This study reviews medical records and PET scans from 496 people with marginal zone lymphoma to see how well PET scans help doctors stage the disease and predict outcomes. Researchers will compare PET results with CT scans and other tests. The goal is to better understand the rol…